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Human epidermal growth factor receptor 2 (Her2/neu) is a biomarker that is overexpressed in human 
breast cancers. A quantum dots (QDs) based genosensor for Her2/neu oncogene was developed with 
gallium telluride QDs and amine-terminated probe ssDNA (NH2-5′-AATTCCAGTGGCCATCAA-3′), 
that is complimentary to the DNA sequence of a section of the ERF gene of HER-2/neu (i.e. 5′-
GAACATGAAGGACCGGTGGGC-3′). The QDs were highly crystalline, 6 nm in size and 3.4 eV in 
median band-gap. The sensor sensitivity and limit of detection values were 10.0 µA ng-1 mL-1 and 0.2 pg 
mL-1 Her2/neu oncogene, respectively. Cytotoxicity studies using A549 human bronchial lung epithelial 
cells indicate that the genosensor can be customised for in vivo application.
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Introduction 
Breast cancer is the most common female cancer both in 
developed and developing countries.1, 2 Invasion and metastasis 
are the root causes of cancer death3 with the initial step being 
the breakdown of extracellular matrix by invading cancer cells 
via a concerted action of proteolytic enzymes (such as matrix 
metalloproteinases, MMPs), particularly the gelatinases MMP2 
and MMP9.4,5 The secretion and activity of these enzymes are 
partially dependent on the human epidermal growth factor 
receptor 2 (HER2) pathway,6,7 which is amplified and 
overexpressed in breast cancer.8 HER2 overexpression drives 
breast cancer cell growth by upregulating the expression of 
MMP2 and MMP9, resulting in accelerated degradation of type 
IV collagen.9,10 
 Currently, immunohistochemistry (IHC) to detect protein 
overexpression and gene amplification using fluorescence in 
situ hybridisation (FISH) are commonly employed approaches 
for assessing HER2 status in clinical specimens. IHC is prone 
to interfering factors, sensitivity issues, high discrepancy 
between laboratories, and subjective interpretation.11-14 IHC is a 
semi-quantitative technique, while FISH is now considered as 
‘‘gold standard’’ for HER2 determination. The latter, however 
is expensive, labour intensive and time-consuming, requiring 
specialized expertise and equipment,11-13,15. Moreover, gene 
amplification detected by FISH does not necessarily indicate 
protein translation and functional expression.11,16,17 Therefore, a 
quantitative, accurate, cost effective and cconvenient method 
for HER2 protein detection is highly desirable.11,13 
 Nanoscience has become one of the most exciting areas in 
scientific research, with experimental developments being 
driven by pressing demands for new technological applications. 
New kinds of nano-materials which could be used in forensic 
science, biomedical diagnostics, electronic and sensor 
technologies, environmental and agri-food industries have been 
proposed. Due to high surface-to-volume ratio, electro-catalytic 
activity, biocompatibility and electron transport properties, 
quantum dots (QDs) are highly attractive materials for ultra-
sensitive detection of biological macromolecules via bio-
electronic or bio-optic transduction.18,19 They possess 
unique optical and electronic properties which are capable of 
producing fluorescence signals that depend on size and 
composition.20 and have applications which range from 
medicine to energy.21,22 Compared with traditional organic 
fluorophores and fluorescent proteins, QDs are superior in 
fluorescence brightness, emission tunability and photo-
bleaching resistance.23 In addition, QDs have broad absorptions 
with narrow emission spectra, and different colors. They can be 
excited simultaneously by a single-light source, with minimal 
spectral overlapping.24, 25 These unique optical properties make 
QDs ideal candidates for multi-color imaging of molecules in 
order to investigate the dynamic cellular processes of cancer 
progression, such as continual cell migration, invasion and 
metastasis.3, 26–28 However, the clinical application of QDs-
based probes in vivo has been limited by potential cytotoxicity 
effects,27–29 and clinical application should firstly involve in 
vitro studies,30 especially in molecular pathology.31 The 
advances of QDs-based probes for breast cancer have 
demonstrated a promising preclinical application in recent 
studies.30, 32–37  
 The focus of this study is demonstration of HER2/neu 
complimentary DNA detection using a Ga2Te3 modified 
electrode surface. This approach opens up development of 
DNA-based genosensors for the detection of transgenes or 
biomarkers for breast cancer. 
 
Experimental Procedures 
Reagents and materials 
Gallium metal (99.99%), tellurium powder (99.99%), sodium 
borohydride (99.99%), 3-Mercaptopropionic acid (MPA, 
99.0%), acetone, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC), N-hydroxysuccinimide 
(NHS), pH 8.00 ± 0.1, perchloric acid (HClO4), sodium 
hydroxide (99.9%) and hydrochloric acid (75%) were all 
purchased from Sigma-Aldrich. 18-21 base oligonucleotide 
DNA sequences were purchased from Inqaba Biotechnical 
Industries (Pty) Ltd., Hatfield, South Africa and Eurogentec 
S.A, Rue du Bois Saint Jean, 5, 4102 Seraing, Dublin). Base 
sequences: Amine terminated DNA with the sequence NH2-5′- 
AAT TCC AGT GGC CAT CAA-3′, was used as the probe 
ssDNA. Target DNA (complementary): 5′-GAA CAT GAA GGA 
CCG GTG GGC-3′, - a section of ERF gene of HER-2/neu. Non 
complementary: 5′-CAT AGT TGC AGC TGC CAC TG-3′. 3-
base mismatch: 5′-GAT CAT GAA GCA CCG GAG GG-3′. The 
oligonucleotide DNA stock solutions were prepared using 
phosphate buffer and stored in a freezer at (-20 °C). Phosphate 
buffer solution (PBS), 0.1 M, pH 7.4 was prepared from 
anhydrous potassium hydrogen phosphate (K2HPO4) and 
potassium dihydrogen phosphate (KH2PO4). Deionized water 
(18.2 MΩ) purified by a Millipore system (Synergy) was used 
for aqueous solution preparations. 
 
Synthesis of Ga2Te3 quantum dots  
3.87 g of Ga metal and 2 mL of concentrated HClO4 were 
added to a round bottomed flask and refluxed under constant 
stirring for 8 h at 120 °C, after which a white precipitate of 
Ga(ClO4)3.6H2O was formed. 380 mg of the Gallium salt was 
then dissolved in 20 mL of distilled water followed by addition 
of 138.9 µL of capping agent MPA (concentrated solution : 
4.06 µM). The pH of the solution was adjusted to 12 (using 1.0 
M NaOH) and saturated with N2 for 1 h.  
 Te2- was prepared by mixing 32 mg of Te powder with 16.0 
mg sodium borohydride dissolved in 20 mL distilled water, 
under an inert atmosphere (N2). The mixture was then stirred 
continuously (8 h) at room temperature under nitrogen 
saturation, after which a dark purple solution was formed. 
Freshly prepared Te2- was added dropwise into the nitrogen 
saturated Ga(ClO4)3/MPA solution followed by reflux for 4 h 
resulting in a yellow solution (Ga2Te3 quantum dots in 
solution).  
 For X-ray diffraction (XRD) analysis, the solution was 
cooled in an ice bath, following a 4 h reflux (100 °C) and 
precipitated by adding acetone (35 mL), drop-wise to the 
reaction mixture under continuous stirring. The precipitate was 
collected via centrifugation (10 min, 14,000 rpm) and the 
materials washed with water several times in order to remove 
free ions, using a combination of sonication and centrifugation. 
70% yield of the powdered quantum dots (Ga2Te3) was realised 
and re-dispersion was possible in 0.2 M phosphate buffer (pH 
7.4) when required. 
 
 
Preparation of Ga2Te3-MPA/Au and Ga2Te3-MPA/GCE 
electrodes. 
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Gold disk electrode (Au) and glassy carbon electrode (GCE) 
were thoroughly cleaned by polishing using 1.00, 0.30 and 0.05 
µm alumina powders and rinsing with de-ionized water. This 
was followed by sonication in de-ionised water for 5 min. The 
electrodes (Au and GCE) were drop-coated with MPA capped 
Ga2Te3 QDs solution, dried at 35 °C for 1 h, followed by gentle 
washing with de-ionised water to remove any loose material. 
The electrodes are labelled as Ga2Te3-MPA/Au and Ga2Te3-
MPA/GCE. Phosphate buffer solution (0.2 M, pH 7.4) was used 
as electrolyte for electrochemical measurements.  
 
DNA genosensor fabrication (dsDNA/Ga2Te3-MPA/Au)  
 
The QDs modified gold electrode (Ga2Te3-MPA/Au) was 
activated via EDC-NHS steps (Scheme I) prior to ssDNA 
attachment. The hybridisation step was performed by 
immersing the probe-modified gold electrode in different 
concentrations 0.1 nM to 8 nM of the target DNA 
(complimentary) for 5 min. The as prepared electrode is 
labelled as dsDNA/Ga2Te3-MPA/Au. A CV of the hybridised 
electrode was recorded following the incubation step. The same 
protocol was applied for hybridisation reactions of the probe-
modified electrode with, 1-base mismatch sequence, 3-base 
mismatch and non-complimentary DNA. 
 
Instrumentation and electrochemical measurements  
 
The surface morphology, size and distribution of the 
synthesised Ga2Te3 quantum dots was scrutinised using 
transmission electron microscope  (TEM, JEOL 2011) in order 
to determine particle size, shape, and distribution and 
crystallinity. The TEM was operated at 200 kV using a LaB6 
filament equipped with a Gatan multiscan camera 794 and the 
sample was dropcast onto Cu grids. Elemental analysis was 
enabled using EDX/EDS and X-ray diffraction (XRD) 
performed using a Rigaku D/MAX-PC 2500 X-ray 
diffractometer with a CuKα (λ = 1.54 Å) radiation source 
operating at 40 kV and 200 mA. Fourier Transform Infrared 
Spectroscopy (FTIR) experiments were performed on a Perkin 
Elmer spectrometer (Spectrum 100), Fluorescence experiments 
were performed on (Type FL3- 2IHR) and UV/Vis absorption 
spectroscopy was performed using BioTek Synergy H1-Hybrid 
detector.  
 Electrochemical experiments {cyclic voltammetry (CV) and 
electrochemical impedance spectroscopy (EIS)} were 
performed using a CH Instruments Bioanalytical System 660 
(Model No: 100B). A three-electrode electrochemical cell 
comprising a platinum counter electrode, Ag/AgCl reference 
electrode, a glassy carbon (GCE, 0.0707 cm2) or gold (Au, 0.02 
cm2) working electrode and 0.1 M PBS (pH 7.4) as electrolyte, 
were used in all electrochemical experiments. 
 
  
 
 
Scheme I. 
 
Results and Discussion 
 
Surface morphological and structural characterisation 
The surface morphology, and particle size of the synthesised 
Ga2Te3 quantum dots were characterised using TEM, HR-TEM 
and STEM (Fig. 1 (a-f)) and provide evidence of good 
dispersion, indicating that the synthetic route was successful in 
avoiding agglomeration. Fig. 1 (a, b, and f) shows the TEM and 
HR-TEM images of the Ga2Te3 QDs.  From the TEM and 
HRTEM data, the average diameter (n = 10) of the QDs was 
estimated to be 5 ± 0.5 nm. HRTEM images showed the uni-
directional lattice fringes (d spacing = 0.2 nm), confirming the 
mono-crystallinity of the material. The FFT image is shown in 
Fig. 1 (e) and the results are in good agreement with HRTEM 
with regard to the mono-crystallinity of the QDs. The energy-
dispersive X-ray spectroscopy (EDS, Fig. 1g) analysis further 
confirms the presence of Ga and Te in Ga2Te3 QDs sample 
which are the main components of the material. Copper was 
observed in the EDS spectrum as a result of the sample 
preparation (sample stub) used in TEM/EDS analysis. 
 XRD analysis was employed for the structural and size 
verification of the Ga2Te3. XRD analysis (Fig. 2A) shows the 
diffraction pattern with peaks positions corresponding to crystal 
planes (111), (200), (220), (311), (222), (400), (420) and 
(333).38-39 From a careful analysis of the peak positions, lattice 
parameters and in accordance with the literature,38-40 XRD 
patterns of the nanodots were indexed/associated to the cubic 
phase (zinc blende) structure for Ga2Te3 with lattice constant, a 
= 5.89Å. In the XRD patterns, the (111) plane was found to be 
very clear and abundant which indicates preferential growth of 
the crystallites. The average size was calculated using the 
Scherrer equation:41.  
                                                    
                                 
θβ
λ
cos
9.0
=d    ...............................(1) 
where d is the crystallite size, λ is the wavelength of X-ray used 
(1.5418Å), β is the full width at half maximum and θ is Bragg’s 
angle of reflection. The average particle size calculated from 
equation (1) was 6 nm, which is in agreement with the average 
size obtained from the HRTEM analysis. The peak at 57.02 
degrees could be assigned to (321/2), corresponding to a 
chalcopyrite structure, indicating the existence of chalcopyrite-
type orderings in the Ga2Te3 crystals.38 Some additional peaks 
(Fig. 2A) were observed in the diffraction pattern which could 
be due to either different Te species or the existence of 
chalcopyrite-type orderings, and this requires further 
investigation.  
 Surface capping and functionalisation of quantum dots was 
intended to: stabilise the quantum dots, lower or even eliminate 
toxicity, prevent agglomeration and aid solubilisation. Here 
MPA (3-mercaptopropionic acid) acted as capping agent and it 
was expected that the thiol group (-SH) of the MPA would 
associate with the hydrophobic surface of the quantum dots42 
while the carboxylic acid group (-COOH) extends into solution 
to make the quantum dots more hydrophilic. Fig. 2B contains 
the FTIR spectrum of MPA which has vibrational stretches at 
3000, 2500, 2000 and 1500 cm-1 due to OH, -SH, C=O and C-
H, respectively. Compared to the control (MPA alone, Fig 
2B(a)), the intensity of -SH stretching in the quantum dots 
sample (Ga2Te3-MPA, Fig. 2B(b)) decreased with a slight shift 
in wavenumbers, whilst the uncapped QDs (Ga2Te3, Fig. 2B(b)) 
showed no vibrational stretches as expected, indicating that the 
quantum dots (Fig. 2B(c)) were sufficiently capped with MPA. 
 
 
 
Fig 1. 
 
 UV/Vis and fluorescence studies (Fig. 3) were carried out in 
order to investigate the absorption, emission and excitation 
wavelength of the quantum dots. The λmax of MPA-Ga2Te3 was 
observed at 238 nm and that of MPA alone was observed at 298 
nm, (Fig. 3(a)). The behaviour suggests that the absorption of a 
photon at this wavelength by MPA-Ga2Te3 QDs caused 
electronic transition from the valence band to the conduction 
band, thereby leaving an electron-hole pair (exciton). Electrons 
in the valence band are tightly coupled with their respective 
nuclei, whereas electrons in the conduction band are slightly 
separated from their nuclei, thereby allowing free electronic 
motion within the solid.  
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Fig. 2 (A) and (B) 
 
   
 The effect of the refluxing (during QDs synthesis) time (for 
2-16 h, at 100 °C) was also monitored and the results are shown 
in Fig. 3a for absorption peaks at 238 nm (2 h), 241 nm (8 h) 
and 340 nm (16 h). This red shift over longer refluxing period 
indicate size increment and decrease in the band gap energies. 
This increment in size is due to quantum confinement effects, 
which may be observed when the size is sufficiently small - the 
energy level spacing of the nanocrystal exceeds a KBT (KB is 
Boltzmann’s constant and T is temperature) value of 1.380648 
×10-23 J K-1.43 This effect allows the tuning of the energy-band 
gap with respect to size of quantum dots. 
 Fluorescence analysis (Fig. 3(b-c)) of Ga2Te3-MPA 
produced emission at 310 nm and excitation at 226 nm, while 
MPA alone was had corresponding values at 280 nm and 334 
nm. The Ga2Te3 QDs was found to be blue shifted (by 50 nm) 
and the shift in wavelength was associated with Stokes shift. 
The energy of the emitted (310 nm) and excited (226 nm) 
species and the band gap energy (Eg) from the fluorescence and 
UV-visible analysis were calculated using the following 
equation: 
 
                           
λ
hc
Eg =
   .......................................  (2) 
 
where Eg is the band gap energy, h is the Planck constant (6.626 × 
10-34 J s  or 4.136 × 10-15 eV s), c is the speed of light = 3.0 × 108 cm 
s-1, λ is the wavelength (430 × 10-9 m). The energy of the emitted 
electron was calculated to be 4.62 × 10-22 J for excitation and 5.37 × 
10-22 J for the absorption. The band gap of the material was 
calculated to be 3.3 eV and 3.5 eV from fluorescence and UV/visible 
data, respectively. These values were found to be comparable and 
are in good agreement with the literature values.38-41, 44,45,46-57 The 
band gap value suggests that the material is electrically conductive 
(i.e. it is a semiconductor). 
  
 
 
Fig 3 (a), (b and c) 
 
 
Electrochemical characterisation  
Redox properties Ga2Te3-MPA QDs immobilized on GCEs were 
investigated prior to DNA sensing. Fig. 4A shows the CVs of the 
bare GCE; and MPA-, Ga2Te3- and (Ga2Te3-MPA)-modified GCEs. 
From the comparison of MPA-capped vs. uncapped QDs samples 
(Fig. 4A (c and e)), a shift in peak potential (for Te oxidation process 
at Ep = 270 mV) as well as significant increment in anodic and 
cathodic current (Ep = -700 mV for Ga3+   reduction wave) were 
observed, which may be attributed to the particle size effect. The 
capping agent may also have a co-catalytic effect, which is evident 
by an increase in the peak current of the capped (Ga2Te3- 
MPA/GCE) compared to the uncapped (Ga2Te3/GCE) QDs. For 
comparison cyclic voltammetry of ssDNA/GCE in phosphate buffer 
solution was also recorded (Fig. 4B).  GCE was chosen specifically 
for this purpose due to the occurrence of gold oxidation and 
reduction peak currents which might interfere with the ssDNA peak 
currents. 
Fig. 4C contains the cyclic voltammograms (CVs) of (a) 
Te/GCE, (b) Ga2Te3-MPA/GCE, (c) ssDNA/ Ga2Te3-MPA/GCE and 
(d) bare GCE; in phosphate buffer solution. Ga2Te3-MPA/GCE gave 
an anodic peak current at 350 mV, which shifted to 500 mV, upon 
the introduction of ssDNA. The ssDNA oxidation (Fig. 4B) was also 
observed at around this potential (400 mV) as well as 850 mV, and 
was associated with the guanine redox process (Fig. 4B (a and b)). 
Since a potential shift and a catalytic effect were observed at the 
peak occurring at 400 mV, it was used to study the interaction of the 
probe-ssDNA modified electrode with the target-ssDNA. 
Comparative electrochemical studies were also performed with Au 
electrodes. A clear reduction wave at -120 mV (peak labelled as c, 
Fig. 4D) was observed for the Au electrode, which is associated with 
the oxidation products of the QDs. The Au working electrode was, 
therefore, employed for further genosensor studies. 
 Scheme II represents the reaction mechanism for genosensor 
fabrication on Au electrode (which was selected due to its 
compatibility with the MPA capped QDs). The Au surface provides 
coupling sites for the amine-modified DNA attachment via the 
formation of amide linkages. The coupling was promoted by 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC) and 
N-hydroxysuccinimide (NHS). 
 
 
 
Fig 4. (A), (B), (C) and (D) 
 
 
 
 
Scheme II: (A) The mechanism of the reaction of Ga2Te3-
3MPA and probe-ssDNA with linkers (EDC/NHS). (B) The 
schematic diagram for the interaction of ssDNA/Ga2Te3-
MPA/Au with target-ssDNA. 
 
 
 
Fig 5. (A) and (B) 
 
Fig. 5A depicts the Nyquist plots of the EIS data for experiments 
performed with bare Au, Ga2Te3-MPA/Au and ssDNA/Ga2Te3-
MPA/Au electrodes. The aim of the EIS experiment was to 
investigate the behaviour of the modified and unmodified electrodes 
at an applied potential of 400 mV (observed from CV measurements, 
Fig. 4A). The Rct values were calculated by fitting the EIS data to the 
electrical circuit diagram drawn as Fig. 4A inset. The Rct values for 
bare Au, Ga2Te3-MPA/Au and ssDNA/Ga2Te3-MPA/Au were 11.93, 
9.02 and 10.32 Ω, respectively. This indicates a more conducting 
surface (faster charge transport at electrode/solution interface) for 
Ga2Te3-MPA/Au, relative to both the bare Au and ssDNA/Ga2Te3-
MPA/Au. Rct represents the resistance to the charge transfer between 
the electrolyte and the electrode and contains information on the 
electron transfer kinetics of the redox probe at the electrode-
electrolyte interface. The surface coverage (θ) of Ga2Te3-MPA/Au 
was 0.78 cm s-1 and the electron transfer rate constant (ket) values for 
bare Au, Ga2Te3-MPA/Au and ssDNA/Ga2Te3-MPA/Au (at 400 
mV) were calculated to be 1.79 × 10-11 s-1, 2.22 × 10-10 s-1 and 1.48 × 
10-10 s-1, respectively.  
The Bode plot (Fig. 5B) confirms the electrical properties 
of the nano-material and is in agreement with the Nyquist plot, 
where the modified electrode showed improved conductivity based 
on the phase angle of the material – 0 θ (insulator) , 20-45 θ 
(semiconductor) and 90 θ (conducting - pure metal). The actual 
phase angles for bare Au, Ga2Te3-MPA/Au and ssDNA/Ga2Te3-
MPA/Au were found to be 79 θ, 71 θ and 63 θ, respectively. The 
Ga2Te3-MPA/Au is relatively more conducting due to the 
contributions of  Rs, Rct and CPE (Rs + Rct + CPE) in the electrical 
circuit, which are more predominant than in ssDNA/Ga2Te3-
MPA/Au which has a mixture of Rs, and Rct (Rs + Rs + Rct) circuit 
elements; meaning that the solution resistance is more predominant 
than charge transfer resistance. (Rs, Rct and CPE are the solution 
resistance, charge transfer resistance and constant phase element, 
respectively). The total impedance, Z, data of Fig. 5B confirmed the 
conductive nature of the Ga2Te3-MPA/Au. At log F = 0, the log 
Z(Ga2Te3-MPA/Au) =  4.3, whereas log Z(bare Au) = log 
Z(ssDNA/Ga2Te3-MPA/Au) = 4.7. This means that when the 
electrode systems were subjected to minimal frequency effects the 
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QDs (which has additional metals in the system and without 
insulating oligonucleotide chains) is more conducting than the 
semiconducting gold electrode. There is a shift log 2 magnitude shift 
(increase) in frequency on changing from Ga2Te3-MPA/Au (1.74) 
electrode to ssDNA/Ga2Te3-MPA/Au (1.05) genosensor, due to the 
incorporation of the insulating probe-ssDNA in the sensor system. 
 
Genosensor response studies 
Cyclic voltammetry was used to study the binding event of the 
probe-ssDNA and the target-ssDNA (i.e. the complementary Her2 
oncogene). Voltammograms with redox properties of gold electrode 
were observed with an oxidation peak potential (Ip,a) at Ep = 800 mV 
and a reduction peak potential (Ip,c) at Ep = 500 mV, Figure 6 A, b′, 
b′′ and 6 C, b. Shoulders or small reduction peaks were observed at 
oxidation peak potential (Ip,a) of Ep = -100 mV which can be due to 
the products of QDs, Ep = -500 mV which was associated with redox 
properties of Ga3+ (Figure 6 A, d and 6 C, a) and at Ep = -850 mV 
which was associated with redox properties of Te2-, Figure 6 A, e. 
The attenuation of the anodic peak current of ssDNA /Ga2Te3-
MPA/Au at 400 mV (Fig. 6A (a)) due to the electrostatic interaction 
between the genosensor and the Her2 oncogene, was used to study 
the genosensing process. This interaction was made possible by the 
covalent attachment of the probe-ssDNA on the surface of the Au 
electrode. To achieve this, a probe-DNA and the surface onto which 
the it is to be immobilized may be modified by introducing reactive 
functional groups that will allow covalent coupling.47 Several 
functionalities on either the electrode or the probe-ssDNA have been 
reported for stable anchoring of the probe on the electrode surface. 
Commonly used reactive functional groups include thiol, carboxyl 
and amino groups.48 Covalent coupling via functionalised probe or 
electrode surfaces are usually accompanied by chemical activation 
steps.49,50 
 
Fig 6. (A), (B), (C) and (D) 
 
 
Table 1. Comparison of genosensor with other methods for 
HER2/neu oncogene determination (The original values are all 
converted to ng mL-1) 
Technique DLR  
(ng mL-1)  
 
LOD 
 (ng mL-1) 
Sensitivity 
 (µA ng-1 mL-1) 
Genosensor:  
ssDNA/Ga2Te3-MPA/Au 
0.03-0.55 0.0002 -- 2-10 
PZT/glass PEMS [29] - 13  111  
PCR [19] 28  0.06  5.5  
ELISA [26] 185-46250  100  0.1  
Nanoimmunoassay [52] 2-20000 1000 180 
Opto-Fluidic Ring 
Resonator (OFRR)[53] 
13-100 10 20 
Biosensor: Surface 
Acoustic Wave 
(SAW)[54] 
13-20 10 - 
 
 
The binding-event that occurred after the introduction of 
0.5 nM of Her2 oncogene in cell system containing the genosensor is 
presented in Fig. 6A (a). The plot showed a decrease in current as 
the concentration increases, which confirmed the binding of the 
analyte and the probe-ssDNA at the electrode interface. A shift in 
peak potentials (̴ 50 mV) was also observed, which is characteristic 
of an electrode reaction involving slow electron transfer kinetics. 
The genosensor calibration plot is presented in Fig. 6B. It was clear 
from the plot that the sensor reached its point of saturation around 3 
nM. The sensitivity of the genosensor was found to be 2.8 × 10-2 µA 
ng-1 mL-1, the dynamic linear range (DLR) was calculated to be 0.5-
3.0 nM and its limit of detection (LOD) was calculated to be 0.7 pg 
mL-1.  
 
 
 
Fig. 7  
 
Square wave voltammetry (Figure 6C) showed two 
unresolved peaks, at 400 mV and at 800 mV. These two peaks are 
due to the ssDNA/Ga2Te3–MPA and the unreacted tellurium (Te
o). 
The two peaks merged into single distinctive peak after the addition 
of target analyte. After each addition of the target analyte, the peak 
current at 400 mV decreased with increasing concentration of 
analyte (Fig. 6C). From the calibration curve (Fig. 6D), the 
sensitivity and the DLR of the system were found to be 10 µA ng-1 
mL-1 and 0.1-2.0 nM, respectively (r2 = 0.98). The LOD of the 
genosensor from the SWV was calculated to be 0.2 pg mL-1. Table 1 
shows the comparison of the genosensor parameters with literature 
values for other methodologies for determining the HER2/neu 
oncogene. The genosensor’s DLR is comparable to those reported in 
the literature for other methods. More importantly, the DLR values 
of the genosensor are within the physiological HER2/neu oncogene 
concentrations in the blood of normal (2-15 ng mL-1) and breast 
cancer (15- 75 ng mL-1) patients.51  
Cross-reactivity (selectivity and non-specific adsorption) 
experiments were performed to assess whether the ssDNA/Ga2Te3-
MPA/Au responded selectively to the complementary target. In this 
work, the complementary target DNA, the single-base mismatch 
target, the three-base mismatch target and the non-complementary 
sequence DNA were used to study the sequence-specificity of the 
sensor. The CVs of the genosensor (ssDNA/Ga2Te3- MPA/Au) 
responses for 5 nM of the different target DNA molecules are plotted 
in Fig. 7. The oxidation signal responded differently with different 
analytes. These findings indicate that some of the analytes 
hybridization did not occur. A decrease in signal was observed when 
the probe electrode was hybridised with the 3-base mismatch and 
non-complimentary sequence, suggesting that hybridisation occured 
at the electrode interface. However, there was a high decrease in 
signal after the probe DNA was hybridised with both the 
complimentary and 1-base mismatch sequences. This could be due to 
the fact that the target analytes and the capture probe are fully 
bound. These results demonstrated that the complementary target 
sequence could form double-stranded DNA with the probe-DNA 
producing a significant decrease in signal. The stability and 
reproducibility of the probe-modified electrode was done by keeping 
the electrode for 5 days in the freezer (-20 °C) and cycling the 
modified electrode 20 times, Fig. 8. After CV analysis, the same 
electrode was used after several days and the oxidation peak of the 
sensor at +250 mV was monitored. The peak current of the electrode 
initially decreased slightly but remained constant after several 
cycles. Statistical analyses were performed based on the stability of 
the sensor. The average sum of peak currents (n = 9) were calculated 
to be 16.98, whilst the calculated standard deviation (SD) and the 
mean values were calculated to be 0.23 and 1.69, respectively. The 
results suggest that the genosensor only degraded by 23%. Thus the 
behaviour of the modified electrode proved that the electrode can be 
used for number of analysis.  
 
 
Fig. 8 
 
Conclusion  
Novel water soluble gallium telluride quantum dots (MPA-Ga2Te3) 
were successfully synthesised and characterised using surface, 
structural, electrochemical and spectroscopic techniques. UV-visible, 
EIS and fluorescence techniques were able to determine the 
conductivity of the quantum dots, and semiconductor properties of 
the materials were confirmed. The bifunctional amphiphilic 
molecule (3-mercaptopropionic acid) used as capping agents 
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rendered the quantum dots biocompatible, soluble and stable. 
Electrostatic repulsion arising from dehydrogenated carboxyl groups 
on the surface of the quantum dot particles kept them non-
agglomerated. Retention of the capping agent on the capped-
quantum dot surface was confirmed by FTIR studies, which showed 
characteristic bands related to C-H, C=O, -SH as well as –O-H 
groups. By doing comparative studies between capped QDs, 
uncapped QDs and MPA, the observed bands were present in MPA 
alone and capped QDs thus confirming the presence and attachement 
of MPA on the QDs. In addition, the intensity of –SH band 
decreased or disappeared due to the strong affinity between the metal 
precursor gallium (Ga) and sulphur (S). Electrochemical 
interrogation of the Ga2Te3-MPA/Au electrodes and the HER2/neu 
oncogene sensor (ssDNA/Ga2Te3-MPA/Au) were perfomed. The 
proposed sensor showed a sensitivity of (10.0 µA ng-1 mL-1) and 
LOD (0.2 pg mL-1) as calculated from SWV measurements. The 
detection limit of the genosensor was significantly lower than what 
is reported literature values and most importantly well below 
physiological limits (FDA approved) for Her2/neu detection (2-15 
ng mL-1). Compared to other analytes, the sensor proved to be 
specific to the complimentary analyte. The genosensor is very 
promising and have the potential of being adapted for the sensitive 
detection of other transgenes or biomarkers for breast cancer. This 
experimental success with analytical (buffer-based) samples should 
encourage future work with clinical samples. 
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Fig 1. TEM analysis for Ga2Te3 quantum dots sample; (a-f) TEM images and (g) EDS spectrum for Ga2Te3. 
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Fig. 2 (A) X-ray diffraction pattern of Ga2Te3 quantum dots. (B) FTIR spectra for (a) MPA, (b) Ga2Te3-MPA. 
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Fig 3 (a) UV-visible spectra of Ga2Te3-MPA in solution (before and during/after reflux). (b and c) Fluorescence 
spectra of Ga2Te3 showing both emission and excitation in solution.  
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Fig 4. Cyclic voltammetric responses of electrode systems.  (A)  CVs of (a) bare GCE (b), MPA/GCE, (c) 
Ga2Te3/GCE and (d) Ga2Te3-MPA/GCE. (B) CV of ssDNA/GCE. (C) CVs of (a) Te/GCE, (b) Ga2Te3-MPA/GCE, 
(c) ssDNA/Ga2Te3-MPA/GCE and (d) bare GCE. (D) CVs of bare Au and ssDNA/Ga2Te3-MPA/Au. Experiments 
were performed in 0.1 M PBS (pH = 7.4) at 25 mV s-1. 
 
 
Page 11 of 17 Analytical Methods
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
A
na
ly
tic
al
M
et
ho
ds
A
cc
ep
te
d
M
an
us
cr
ip
t
 
Fig 5. (A) Nyquist plots of bare Au (red symbols), Ga2Te3-MPA/Au (blue symbols) and ssDNA/Ga2Te3-MPA/Au (black 
symbols) electrodes in 0.1 M PBS (pH = 7.4). (B) The corresponding Bode plots of the EIS data in (A). 
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Fig 6. Genosensor (ssDNA/Ga2Te3-MPA/Au) responses to Her2 oncogene: (A) CVs, (B) calibration curve from 
CV data, (C) SWV and (D) calibration curve from SWV data. Typical concentrations of Her2 oncogene used are 
indicated in the graph. Experiments were performed in 0.1 M PBS (pH = 7.4) at 25 mV s-1. 
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Fig. 7 Cross-reactivity of genosensor. Conditions are as in Fig. 6. 
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Fig. 8 Stability of genosensor. Conditions are as in Fig. 6. 
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Scheme I. Preparation and response procedures of  ssDNA/Ga2Te3-MPA/Au genosensor. 
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Scheme II: (A) The mechanism for the reaction of Ga2Te3-3MPA and probe-ssDNA with linkers (EDC/NHS). (B) 
The schematic diagram for the interaction of ssDNA/Ga2Te3-MPA/Au with target-ssDNA. 
 
Page 17 of 17 Analytical Methods
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
A
na
ly
tic
al
M
et
ho
ds
A
cc
ep
te
d
M
an
us
cr
ip
t
